Universidad de Guanajuato
Quick facts
Marketed products
- Chlorhexidine gluconate at 0.125%
- Glargine and Lispro insulin
- Linagliptin / Metformin Oral Tablet · Diabetes
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.
Phase 3 pipeline
- Antiseptic substantivity · Oral Health / Dentistry
Antiseptic substantivity refers to the prolonged antimicrobial activity of an antiseptic agent that persists on oral tissues after application. - Chlorhexidine gluconate at 0.12% · Infectious Disease / Oral Health
Chlorhexidine gluconate is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, leading to rapid bactericidal and bacteriostatic effects. - Chlorhexidine gluconate at 2% · Infectious Disease / Antisepsis
Chlorhexidine gluconate is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, leading to rapid bactericidal and bacteriostatic effects. - chlorhexidine in isopropyl alcohol · Infection prevention/Dermatology
Chlorhexidine disrupts bacterial cell membranes and inhibits metabolic processes, providing broad-spectrum antimicrobial activity.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: